Lecalpin

Lercanidipine Hydrochloride, the active ingredient in Lecalpin, is a calcium channel blocker presented as an oral tablet for systemic use. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure and reduce cardiovascular risk.

GNH USA supplies Lecalpin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets across Europe, Asia, Africa and the Americas. Customers benefit from comprehensive technical support and on‑time delivery.

Lecalpin, a calcium channel blocker, is used to treat conditions related to elevated vascular resistance.

- Hypertension: Reduces systolic and diastolic blood pressure, aiding long‑term cardiovascular risk management.

Lecalpin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the lower limbs. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Palpitations: awareness of heartbeats.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare occurrence of heart attack. - Hepatic enzyme elevation: abnormal liver function tests. - Allergic reactions: rash, pruritus, or anaphylaxis.

Before initiating therapy with Lecalpin, clinicians should consider several safety measures.

- Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Hepatic impairment: use with caution and adjust dose if necessary. - Elderly patients: start at the lowest effective dose due to increased sensitivity. - Concomitant antihypertensives: monitor for additive blood‑pressure‑lowering effects. - Discontinuation: avoid abrupt cessation to prevent rebound hypertension. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lecalpin can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lercanidipine plasma levels. - Co‑administration with other potent antihypertensives: risk of excessive hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug efficacy. - Grapefruit juice: can elevate systemic exposure. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate antihypertensive effect. - Diuretics: monitor electrolytes and blood pressure.